Blair William & Co. IL Purchases 6,314 Shares of ImmunityBio, Inc. $IBRX

Blair William & Co. IL raised its stake in shares of ImmunityBio, Inc. (NASDAQ:IBRX) by 2.7% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 239,814 shares of the company’s stock after buying an additional 6,314 shares during the quarter. Blair William & Co. IL’s holdings in ImmunityBio were worth $633,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Plancorp LLC purchased a new stake in ImmunityBio in the second quarter worth approximately $717,000. Swiss National Bank boosted its stake in ImmunityBio by 49.8% in the first quarter. Swiss National Bank now owns 410,400 shares of the company’s stock worth $1,235,000 after buying an additional 136,400 shares in the last quarter. Nuveen LLC purchased a new stake in ImmunityBio in the first quarter worth approximately $1,083,000. Vanguard Group Inc. boosted its stake in ImmunityBio by 17.4% in the first quarter. Vanguard Group Inc. now owns 20,344,554 shares of the company’s stock worth $61,237,000 after buying an additional 3,016,325 shares in the last quarter. Finally, Sequoia Financial Advisors LLC bought a new stake in ImmunityBio in the first quarter valued at approximately $60,000. Hedge funds and other institutional investors own 8.58% of the company’s stock.

ImmunityBio Price Performance

ImmunityBio stock opened at $2.53 on Friday. ImmunityBio, Inc. has a one year low of $1.83 and a one year high of $7.48. The stock has a market capitalization of $2.49 billion, a PE ratio of -5.27 and a beta of 0.27. The business’s fifty day moving average is $2.50 and its 200 day moving average is $2.62.

ImmunityBio (NASDAQ:IBRX) last announced its earnings results on Tuesday, August 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.10). The firm had revenue of $26.43 million during the quarter, compared to analysts’ expectations of $21.95 million. As a group, sell-side analysts expect that ImmunityBio, Inc. will post -0.92 EPS for the current fiscal year.

Analysts Set New Price Targets

IBRX has been the subject of a number of recent analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of ImmunityBio in a report on Tuesday. HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of ImmunityBio in a report on Wednesday, September 10th. Finally, D. Boral Capital restated a “buy” rating and set a $24.00 target price on shares of ImmunityBio in a report on Monday, September 8th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $10.75.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.